Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY21 results · Oct–Dec 2020
Lincoln Pharmaceuticals reported revenue from operations of ₹112.19 crore (up 17.3% from Q3 FY20) and net profit of ₹13.37 crore (up 31.4% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.19 | 95.64 | +17.3% | 122.29 | −8.3% |
| Other income | 1.06 | 2.37 | −55.0% | 1.22 | −12.7% |
| Total income | 113.26 | 98.01 | +15.6% | 123.51 | −8.3% |
| Profit before tax | 18.16 | 12.05 | +50.7% | 27.39 | −33.7% |
| Net profit for the period | 13.37 | 10.18 | +31.4% | 20.20 | −33.8% |
| EPS, basic (₹) | 6.68 | 5.09 | +31.3% | 10.10 | −33.8% |
| Net margin (%) | 11.9 | 10.6 | 16.5 |
Standalone
- Filed with BSE
- 02 Feb 2021, 15:43 IST
- Board meeting
- 02 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE